Andie
New member
"The U.S. Food and Drug Administration on Friday requested that the makers of a class of asthma drugs called leukotriene receptor agonists place a "precaution" on the drugs' labeling, warning of the potential for neuropsychiatric events.
The drugs in question include the blockbuster medication Singulair (montelukast), as well as Accolate (zafirlukast). Zyflo and Zyflo CR (zileuton), drugs in a class known as leukotriene synthesis inhibitors, are also included in the labeling change.
The reported neuropsychiatric events include postmarket cases of agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior [including suicide], and tremor"
Full story here:
http://www.forbes.com/feeds/hscout/2009/06/12/hscout628062.html
The drugs in question include the blockbuster medication Singulair (montelukast), as well as Accolate (zafirlukast). Zyflo and Zyflo CR (zileuton), drugs in a class known as leukotriene synthesis inhibitors, are also included in the labeling change.
The reported neuropsychiatric events include postmarket cases of agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior [including suicide], and tremor"
Full story here:
http://www.forbes.com/feeds/hscout/2009/06/12/hscout628062.html